RSLBF Stock Chart & Stats
$23.58
$0.00(0.00%)
At close: 4:00 PM EST
$23.58
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$16.39 - $38.95
Previous CloseN/A
Volume27.00
Average Volume (3M)3.00
Market Cap
$603.99M
Enterprise Value$6.50K
Total Cash (Recent Filing)$439.30M
Total Debt (Recent Filing)$377.30M
Price to Earnings (P/E)26.0
Beta0.92
Next Earnings
Aug 13, 2026EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend Yield1.91%
Share Statistics
EPS (TTM)6.54
Shares Outstanding30,799,536
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio2.87
Price to Book (P/B)7.93
Price to Sales (P/S)5.81
P/FCF Ratio21.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.81
Revenue Forecast (FY)$146.86M
Bulls Say, Bears Say
Bulls Say
High Profitability & ROEConsistent double-digit net and EBIT margins combined with high ROE indicate durable operating efficiency and strong capital returns. These fundamentals support reinvestment in product development, sustain shareholder distributions, and provide a margin cushion through cyclical periods.
Recurring Software License & Maintenance ModelA licensing model with recurring maintenance and service revenue creates predictable, annuity-like cashflows and high customer lifetime value. The installed base and required clinical integrations support renewals and upsells, enhancing revenue stability over multiple years.
Improving Leverage And Balance-sheet ResilienceControlled leverage and rising shareholders' equity provide financial flexibility to fund R&D and absorb shocks without immediate capital raises. Improved balance-sheet metrics reduce refinancing risk and support strategic investments over the medium term.
Bears Say
Weakening Revenue Growth MomentumA move to slight negative TTM revenue growth marks a deceleration from prior multi-year expansion, limiting the company’s ability to leverage fixed costs and expand operating profits. Persistent slowdown would constrain R&D scale and long-term margin expansion.
Uneven Cash ConversionFree cash flow materially below accounting earnings and mid-0.6x operating coverage mean profits don’t consistently translate into cash. This variability reduces capital allocation flexibility and makes dividends, buybacks or M&A more dependent on periodic cash performance.
Meaningful Absolute Debt LevelEven with an improved D/E ratio, the absolute debt load is material. In a prolonged revenue slowdown or margin pressure, interest and principal obligations could strain liquidity and force tighter spending or capital actions, increasing reliance on steady cash generation.
RaySearch Laboratories AB News
RSLBF FAQ
What was RaySearch Laboratories AB Class B’s price range in the past 12 months?
RaySearch Laboratories AB Class B lowest stock price was $16.39 and its highest was $38.95 in the past 12 months.
What is RaySearch Laboratories AB Class B’s market cap?
RaySearch Laboratories AB Class B’s market cap is $603.99M.
When is RaySearch Laboratories AB Class B’s upcoming earnings report date?
RaySearch Laboratories AB Class B’s upcoming earnings report date is Aug 13, 2026 which is in 17 days.
How were RaySearch Laboratories AB Class B’s earnings last quarter?
RaySearch Laboratories AB Class B released its earnings results on Apr 29, 2026. The company reported $0.159 earnings per share for the quarter, beating the consensus estimate of $0.152 by $0.008.
Is RaySearch Laboratories AB Class B overvalued?
According to Wall Street analysts RaySearch Laboratories AB Class B’s price is currently Overvalued.
Does RaySearch Laboratories AB Class B pay dividends?
RaySearch Laboratories AB Class B pays a Annually dividend of $0.434 which represents an annual dividend yield of 1.91%. See more information on RaySearch Laboratories AB Class B dividends here
What is RaySearch Laboratories AB Class B’s EPS estimate?
RaySearch Laboratories AB Class B’s EPS estimate is 0.19.
How many shares outstanding does RaySearch Laboratories AB Class B have?
RaySearch Laboratories AB Class B has 30,799,536 shares outstanding.
What happened to RaySearch Laboratories AB Class B’s price movement after its last earnings report?
RaySearch Laboratories AB Class B reported an EPS of $0.159 in its last earnings report, beating expectations of $0.152. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of RaySearch Laboratories AB Class B?
Currently, no hedge funds are holding shares in RSLBF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RaySearch Laboratories AB Class B
RaySearch Laboratories AB (publ) is a global medical technology company dedicated to developing cutting-edge software solutions for cancer treatment. Its principal offering, RayStation, is a sophisticated treatment planning system that supports a vast range of clinical activities. These capabilities include automated planning, adaptive therapy, multi-criteria optimization, rapid and accurate dose calculations, OAR dose reduction, robustness modeling, machine learning integration, and support for advanced radiation modalities such as VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic treatments, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also offers RayPlan, another treatment planning system specifically designed for various radiation therapy methods including 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy. For managing oncology workflows, RayCare serves as a dedicated information system. Additionally, RaySearch provides RayCommand, a flexible treatment control system compatible with diverse hardware and designed to manage advanced functionalities of treatment machines and software. To leverage patient data, its cloud-based oncology analytics system, RayIntelligence, converts raw information into valuable insights. RaySearch Laboratories AB (publ) further provides training courses for its products and is headquartered in Stockholm, Sweden.
RSLBF Company Deck
RSLBF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a broadly positive operational and commercial picture: record revenues, strong organic growth, improving profitability and cash position, significant clinical milestones and substantial AI adoption/use cases. Key negatives are material currency headwinds, a book-to-bill ratio below 1 and slower-than-desired traction for RayCare (partly tied to regulatory timing). Management expects margin improvement (target at least 25% for 2026) and a RayCare ramp in coming years, and has strengthened shareholder returns with a higher dividend and a 50% payout policy.View all RSLBF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
1.29% Mutual Funds
― Other Institutional Investors
93.52% Public Companies and
Individual Investors